Price$1.30-1.67 (-56.06%)
2026-02-272026-06-02
News · 26 weeks160%
2025-12-072026-05-31
Mix990d
- SEC Filings6(67%)
- Other2(22%)
- Offering1(11%)
Latest news
25 items- SECSEC Form 10-Q filed by Pulmatrix Inc.10-Q - Pulmatrix, Inc. (0001574235) (Filer)
- SECPulmatrix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Pulmatrix, Inc. (0001574235) (Filer)
- PRPulmatrix Announces First Quarter 2026 Financial ResultsAnnounced merger agreement with Eos SENOLYTIX in MarchClosed private placement of preferred stockFRAMINGHAM, Mass., May 15, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its first quarter financial results for 2026 and provided a corporate update. Peter Ludlum, Interim Chief Executive Offic
- SECPulmatrix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Pulmatrix, Inc. (0001574235) (Filer)
- PRPulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned MergerSeries B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process FRAMINGHAM, Mass., April 21, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), today announced the closing of its previously announced private placement of Series B Convertible Preferred Stock ("Series B Preferred Stock") with an affiliate of Eos SENOLYTIX, Inc. ("Eos"), which such transaction is a part of its planned merger with Eos. The Series B Preferred Stock is convertible into common stock at a price per share of $2.20.
- SECSEC Form D filed by Pulmatrix Inc.D - Pulmatrix, Inc. (0001574235) (Filer)
- SECPulmatrix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pulmatrix, Inc. (0001574235) (Filer)
- SECSEC Form 425 filed by Pulmatrix Inc.425 - Pulmatrix, Inc. (0001574235) (Subject)
- PRPulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve HealthspanCombined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company$19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related diseaseFRAMINGHAM, Mass. and HOUSTON, March 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases, today jointly announced a definitive merger agreement under which Pulmatrix will acquire Eos (the "Merger"). Upon completion of the Merger, the combined company will operate as Eos SENOLYTIX, Inc. and is expected to trade on Nasdaq
- SECPulmatrix Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pulmatrix, Inc. (0001574235) (Filer)
- PRPulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger OpportunitiesCullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agreement - Pulmatrix advances existing discussions on alternative merger opportunities - FRAMINGHAM, Mass., March 2, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced that on February 28, 2026, Cullgen Inc. notifie
- SECSEC Form 10-K filed by Pulmatrix Inc.10-K - Pulmatrix, Inc. (0001574235) (Filer)
- SECPulmatrix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Pulmatrix, Inc. (0001574235) (Filer)
- PRPulmatrix Announces Year-End and Fourth Quarter 2025 Financial ResultsPlans to License or Monetize our Migraine and Inhalation Assets ContinueFRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update. Peter Ludlum, Interim Chief Executive Officer of Pulmatri
- SECPulmatrix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Pulmatrix, Inc. (0001574235) (Filer)
- PRPulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore AlternativesPulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission FRAMINGHAM, Mass., Dec. 18, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced that Pulmatrix and Cullgen Inc. ("Cullgen") have mutually agreed to waive the "No Solicitation" clause in the Merger Agreement signed in November 2024 in order to permit each party to explore alternate transa
- SECSEC Form 10-Q filed by Pulmatrix Inc.10-Q - Pulmatrix, Inc. (0001574235) (Filer)
- SECPulmatrix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Pulmatrix, Inc. (0001574235) (Filer)
- PRPulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation AssetsAs part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule drugs to the lungs by inhalation to treat migraine and respiratory diseases FRAMINGHAM, Mass., Oct. 16, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced third quarter financial results for 2025 and provided a
- SECSEC Form 10-Q filed by Pulmatrix Inc.10-Q - Pulmatrix, Inc. (0001574235) (Filer)
- SECPulmatrix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Pulmatrix, Inc. (0001574235) (Filer)
- PRPulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation AssetsProposed merger anticipated to close in 2025 As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small or large molecule drugs to the lungs by inhalation FRAMINGHAM, Mass., Aug, 6, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced second quarter financial results for 2025 and provided a
- SECSEC Form 425 filed by Pulmatrix Inc.425 - Pulmatrix, Inc. (0001574235) (Subject)
- SECPulmatrix Inc. filed SEC Form 8-K: Other Events8-K - Pulmatrix, Inc. (0001574235) (Filer)
- SECSEC Form 10-Q filed by Pulmatrix Inc.10-Q - Pulmatrix, Inc. (0001574235) (Filer)
PULM FAQ
6 questionsWhat does Pulmatrix Inc. do?
Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal...Where does PULM stock trade?
Pulmatrix Inc. (PULM) is listed on NASDAQ.What sector and industry is PULM in?
Pulmatrix Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pulmatrix Inc. go public?
Pulmatrix Inc. (PULM) completed its IPO in 2014.What companies are similar to PULM?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PULM side-by-side with any of them on Quantisnow.How can I track PULM on Quantisnow?
Quantisnow aggregates Pulmatrix Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PULM to receive live email and push alerts on every new disclosure.